MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Melatonin promoted the therapeutic potential of cisplatin in a rat model of hepatocellular carcinoma: COX-2 and MDM2/p53/miR-155 modulation associated with cytoprotection and tumour regression
Melatonin promoted the therapeutic potential of cisplatin in a rat model of hepatocellular carcinoma: COX-2 and MDM2/p53/miR-155 modulation associated with cytoprotection and tumour regression
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Melatonin promoted the therapeutic potential of cisplatin in a rat model of hepatocellular carcinoma: COX-2 and MDM2/p53/miR-155 modulation associated with cytoprotection and tumour regression
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Melatonin promoted the therapeutic potential of cisplatin in a rat model of hepatocellular carcinoma: COX-2 and MDM2/p53/miR-155 modulation associated with cytoprotection and tumour regression
Melatonin promoted the therapeutic potential of cisplatin in a rat model of hepatocellular carcinoma: COX-2 and MDM2/p53/miR-155 modulation associated with cytoprotection and tumour regression

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Melatonin promoted the therapeutic potential of cisplatin in a rat model of hepatocellular carcinoma: COX-2 and MDM2/p53/miR-155 modulation associated with cytoprotection and tumour regression
Melatonin promoted the therapeutic potential of cisplatin in a rat model of hepatocellular carcinoma: COX-2 and MDM2/p53/miR-155 modulation associated with cytoprotection and tumour regression
Journal Article

Melatonin promoted the therapeutic potential of cisplatin in a rat model of hepatocellular carcinoma: COX-2 and MDM2/p53/miR-155 modulation associated with cytoprotection and tumour regression

2025
Request Book From Autostore and Choose the Collection Method
Overview
Globally, hepatocellular carcinoma (HCC) presents a clinical and financial burden, as it is often diagnosed at a later stage. Cisplatin is one of the most commonly used chemotherapeutics for treating various types of solid tumours; however, it is a double-edged sword due to its cytotoxic effects. Consequently, we hypothesized that combining cisplatin with melatonin could be effective in treating HCC. Additionally, melatonin may mitigate the severe adverse effects of cisplatin on normal cells through its cellular protection, immunomodulation, and antioxidant activities. Forty male adult Wistar rats were randomly divided into five groups: Group 1( n =  8), negative control group. HCC was induced in 32 rats with diethyl nitrosamine and carbon tetrachloride injection. Following induction, rats were divided into group 2 (HCC): diseased control; group 3 (HCC-Cis): HCC rats received cisplatin (2.5 mg/kg I.P. once every week for 3 weeks); group 4 (HCC-Melatonin): HCC rats received melatonin in drinking water (20 mg/L for 3 weeks); and group 5 (HCC-Cis-Melatonin; Combined therapy): the HCC rats received both cisplatin and melatonin . HCC group revealed significant elevation in ALT, AST, and AFP associated with increased TNF-α and MDA levels. Hepatic tissue exhibited a significant increase in VEGF, MDM2, COX-2, and miR-155, and a decrease in caspase-3 associated with hepatic damage, ballooning of hepatocytes, and increased BCL-2 and CD68 immunostaining. Although cisplatin was able to induce HCC apoptosis by COX-2 and MDM2/p53/ miR-155 modulation, it aggravated normal hepatocytic damage that was improved by the antioxidant and anti-inflammatory effects of melatonin. In conclusion, melatonin and cisplatin co-administration may be a viable strategy to preserve liver function by shielding healthy hepatocytes from the cytotoxic effects of cisplatin.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V,SpringerOpen